MODAG GmbH
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.modag.net
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: anle138b (TEV-56286)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 54
- Registration Number
- NCT05532358
- Locations
- π¬π§
Quotient Sciences, Nottingham, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: anle138bDrug: Placebo
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT04685265
- Locations
- π¬π§
Quotient Sciences, Nottingham, United Kingdom
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: anle138bDrug: Placebo
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 68
- Registration Number
- NCT04208152
- Locations
- π¬π§
Quotient Sciences, Nottingham, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath